Saudi, UAE VAT may adversely affect majority of Indian expats

Beijing/Zurich, Mar 4: China has approved the use of Swiss drugmaker Roche's anti-inflammation drug Actemra for patients who develop severe complications from the coronavirus as it urgently hunts for new ways to combat the deadly infection that is spreading worldwide.

China is hoping that some older drugs could stop severe cytokine release syndrome (CRS), or cytokine storms, an overreaction of the immune system which is considered a major factor behind catastrophic organ failure and death in some coronavirus patients.

Actemra, a biologic drug approved in 2010 in the United States for rheumatoid arthritis (RA), inhibits high Interleukin 6 (IL-6) protein levels that drive some inflammatory diseases.

China's National Health Commission said in treatment guidelines published online on Wednesday that Actemra can now be used to treat coronavirus patients with serious lung damage and high IL-6 levels.

Separately, researchers in the country are testing Actemra, known generically as tocilizumab, in a clinical trial expected to include 188 coronavirus patients and running until May 10.

Roche, which donated 14 million yuan ($2.02 million) worth of Actemra during February, said the trial was initiated independently by a third party with the aim of exploring the efficacy and safety of the drug in coronavirus patients with CRS.

It added that there was currently no published clinical trial data on the drug's safety or efficacy against the virus.

More than 3,000 people have died and 93,000 have been infected by the novel coronavirus thought to have originated in Wuhan, China, before spreading to around 90 countries including the United States, Italy, Switzerland, France and Germany.

The Swiss company, for which China is its No. 2 market behind the United States, also makes diagnostic gear to detect the coronavirus.

Since Actemra's approval a decade ago, it has become a go-to drug against other inflammatory conditions, including cytokine storms in cancer patients receiving cell therapies from Novartis and Gilead Sciences.

In 2012 it helped save the life of a young U.S. girl, the first child to be treated for leukaemia with Novatis' Kymriah, from a post-treatment rush of IL-6.

Priced at between $20-30,000 annually for RA according to SSR Health, Roche's medicine is also used for rare juvenile arthritis and giant cell arteritis, or inflammation of the blood vessels.

Mangaluru, July 1: Even as the number of covid-19 positive cases is mounting with every passing day in the region, the Dakshina Kannada district recorded three new deaths due to coronavirus within 24 hours. 

According to sources, a septuagenarian from Bhatkal breathed his last on Wednesday afternoon. He was suffering from diabetes, high blood pressure and battling respiratory illness and pneumonia. His swab was collected and sent for test and the result came as positive.

Earlier in the day, two people had died in Mangaluru due to covid-19: A 31-year-old youth from Bhatkal and a 78-year-old man from Bengre in the city.

The coastal district has witnessed seven deaths from Sunday due to coronavirus.

The 31-year-old man, who was battling health issues due to high blood pressure, breathed his last at a private hospital. His swab was collected after his death. The report came as corona-positive.

The elderly man from Bengre was suffering from diabetes and pneumonia. He passed away at a private hospital.

With this, the total number of death of covid patients in the district reached to 17. Among them two people died due to non-covid reasons.

Thiruvananthapuram, Jan 3: Kerala Chief Minister Pinarayi Vijayan on Friday wrote letters to 11 Chief Ministers including Arvind Kejriwal--Delhi and Mamata Banerjee, West Bengal-- pointing out apprehensions that had arisen among large sections of society consequent to the Citizenship Amendment Act (CAA) - 2019.

In his letter, the Chief Minister said "the need of the hour is unity among all Indians who wish to protect and preserve our cherished values of democracy and secularism."

People from various cross-sections of the society irrespective of any difference they might have, need to stand united in preserving the basic tenets of our polity which form the cornerstone of Indian democracy, he added.

"We are sure that our unity in diversity, which has stood the test of times will ultimately emerge stronger. Kerala has decided to address the apprehensions about NRC and that preparation of NPR will lead to NRC by staying all activities relating to NPR in the State," Mr Vijayan said.

In this regard, the Kerala Legislative Assembly had passed the resolution on December 31, 2019, expressing its concern regarding the impact the CAA will have on the nation's secular credentials, he said.

"The resolution requested the Central Government to repeal the CAA, 2019. States, which have the opinion that CAA should be repealed can also consider similar steps so that it will be an eye-opener to the proponents of the CAA and the NRC," the Chief Minister pointed out.